What Has 30 Years of HIV Vaccine Research Taught Us?

Overview

Journal Vaccines (Basel)

Date 2015 Sep 8

PMID 26344345

Citations 11

Authors

Jose Esparza

Affiliations

Soon will be listed here.

Abstract

When HIV was discovered and established as the cause of AIDS in 1983-1984, many people believed that a vaccine would be rapidly developed. However, 30 years have passed and we are still struggling to develop an elusive vaccine. In trying to achieve that goal, different scientific paradigms have been explored. Although major progress has been made in understanding the scientific basis for HIV vaccine development, efficacy trials have been critical in moving the field forward. Major lessons learned are: the development of an HIV vaccine is an extremely difficult challenge; the temptation of just following the fashion should be avoided; clinical trials are critical, especially large-scale efficacy trials; HIV vaccine research will require long-term commitment; and sustainable collaborations are needed to accelerate the development of an HIV vaccine. Concrete actions must be implemented with the sense of urgency imposed by the severity of the AIDS epidemic.

Citing Articles

Evolution of drug delivery systems: From 1950 to 2020 and beyond.

Park H, Otte A, Park K J Control Release. 2021; 342:53-65.

PMID: 34971694 PMC: 8840987. DOI: 10.1016/j.jconrel.2021.12.030.

Why Does the Molecular Structure of Broadly Neutralizing Monoclonal Antibodies Isolated from Individuals Infected with HIV-1 not Inform the Rational Design of an HIV-1 Vaccine?.

van Regenmortel M AIMS Public Health. 2018; 2(2):183-193.

PMID: 29546103 PMC: 5690275. DOI: 10.3934/publichealth.2015.2.183.

Development of a Preventive HIV Vaccine Requires Solving Inverse Problems Which Is Unattainable by Rational Vaccine Design.

van Regenmortel M Front Immunol. 2018; 8:2009.

PMID: 29387066 PMC: 5776009. DOI: 10.3389/fimmu.2017.02009.

Establishing Correlates of Protection for Vaccine Development: Considerations for the Respiratory Syncytial Virus Vaccine Field.

Kulkarni P, Hurwitz J, Simoes E, Piedra P Viral Immunol. 2018; 31(2):195-203.

PMID: 29336703 PMC: 5863081. DOI: 10.1089/vim.2017.0147.

Structure-Based Reverse Vaccinology Failed in the Case of HIV Because it Disregarded Accepted Immunological Theory.

van Regenmortel M Int J Mol Sci. 2016; 17(9).

PMID: 27657055 PMC: 5037856. DOI: 10.3390/ijms17091591.

References

BERGER E, Doms R, Fenyo E, Korber B, Littman D, Moore J . A new classification for HIV-1. Nature. 1998; 391(6664):240. DOI: 10.1038/34571. View

Pitisuttithum P, Gilbert P, Gurwith M, Heyward W, Martin M, van Griensven F . Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J Infect Dis. 2006; 194(12):1661-71. DOI: 10.1086/508748. View

Lu S . Immunogenicity of DNA vaccines in humans: it takes two to tango. Hum Vaccin. 2008; 4(6):449-52. DOI: 10.4161/hv.4.6.6179. View

Esparza J . A tale of two vaccines: lessons from polio that could inform the development of an HIV vaccine. AIDS. 2012; 27(1):1-5. DOI: 10.1097/QAD.0b013e328359f2c1. View

Pitisuttithum P, Choopanya K, Rerk-Ngnam S . HIV-vaccine research and development in Thailand: evolution and challenges. Vaccine. 2010; 28 Suppl 2:B45-9. DOI: 10.1016/j.vaccine.2009.08.061. View

Plotkin S . Correlates of protection induced by vaccination. Clin Vaccine Immunol. 2010; 17(7):1055-65. PMC: 2897268. DOI: 10.1128/CVI.00131-10. View

Fauci A, Johnston M, Dieffenbach C, Burton D, Hammer S, Hoxie J . HIV vaccine research: the way forward. Science. 2008; 321(5888):530-2. DOI: 10.1126/science.1161000. View

Lawler A, Cohen J . A deadline for an AIDS vaccine. Science. 1997; 276(5316):1184-5. View

Esparza J, Osmanov S, Kallings L, Wigzell H . Planning for HIV vaccine trials: the World Health Organization perspective. AIDS. 1991; 5 Suppl 2:S159-63. View

10.

Merz B . HIV vaccine approved for clinical trials. JAMA. 1987; 258(11):1433-4. View

11.

Zagury D, Leonard R, Fouchard M, Reveil B, Bernard J, Ittele D . Immunization against AIDS in humans. Nature. 1987; 326(6110):249-50. DOI: 10.1038/326249a0. View

12.

Haynes B, Kelsoe G, Harrison S, Kepler T . B-cell-lineage immunogen design in vaccine development with HIV-1 as a case study. Nat Biotechnol. 2012; 30(5):423-33. PMC: 3512202. DOI: 10.1038/nbt.2197. View

13.

Flynn N, Forthal D, Harro C, Judson F, Mayer K, Para M . Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis. 2005; 191(5):654-65. DOI: 10.1086/428404. View

14.

Barouch D, Nabel G . Adenovirus vector-based vaccines for human immunodeficiency virus type 1. Hum Gene Ther. 2005; 16(2):149-56. DOI: 10.1089/hum.2005.16.149. View

15.

Cohen J . AIDS research. Promising AIDS vaccine's failure leaves field reeling. Science. 2007; 318(5847):28-9. DOI: 10.1126/science.318.5847.28. View

16.

Esparza J . A brief history of the global effort to develop a preventive HIV vaccine. Vaccine. 2013; 31(35):3502-18. DOI: 10.1016/j.vaccine.2013.05.018. View

17.

Hu S, Abrams K, Barber G, Moran P, Zarling J, Langlois A . Protection of macaques against SIV infection by subunit vaccines of SIV envelope glycoprotein gp160. Science. 1992; 255(5043):456-9. DOI: 10.1126/science.1531159. View

18.

Montefiori D, Sattentau Q, Flores J, Esparza J, Mascola J . Antibody-based HIV-1 vaccines: recent developments and future directions. PLoS Med. 2007; 4(12):e348. PMC: 2100141. DOI: 10.1371/journal.pmed.0040348. View

19.

Graham B, Matthews T, Belshe R, Clements M, Dolin R, Wright P . Augmentation of human immunodeficiency virus type 1 neutralizing antibody by priming with gp160 recombinant vaccinia and boosting with rgp160 in vaccinia-naive adults. The NIAID AIDS Vaccine Clinical Trials Network. J Infect Dis. 1993; 167(3):533-7. DOI: 10.1093/infdis/167.3.533. View

20.

Esparza J, Yamada T . The discovery value of "Big Science". J Exp Med. 2007; 204(4):701-4. PMC: 2118535. DOI: 10.1084/jem.20070073. View